Qiagen Licenses HandyLab Extraction Technology | GenomeWeb

NEW YORK (GenomeWeb News) – HandyLab said this week that Qiagen has licensed the firm's extraction technology for use in the sample preparation part of its human papillomavirus assays.

Ann Arbor, Mich.-based HandyLab said its extraction technology would be used with the HPV molecular diagnostic tests on Qiagen's QIAensemble and QIAsymphony random access platforms. Financial and other terms of the license were not disclosed.

HandyLab is a privately-held molecular diagnostics company developing products for the decentralization of nucleic acid testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.